Drugs / TA-CIN
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03913117 | Jul 2023 → Dec 2027 expected | cervical adenosquamous carcinoma, cervical squamous intraepithelial neoplasia | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 1 | NCT05132803 | Aug 2021 → Jan 2022 | virus associated tumor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded |
| Phase 1 | NCT02405221 | Apr 2019 → Dec 2024 | cervical carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03911076 | May 2019 → Jun 2022 | cervical adenosquamous carcinoma, cervical squamous intraepithelial neoplasia | PapiVax Biotech, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TA-CIN | “TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)” NCT03911076 ↗ |
| Modality | Vaccine | “TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.” NCT02405221 ↗ |
| Route | Intramuscular | “TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.” NCT02405221 ↗ |